Impact of Brokerage Rating on Ionis Pharmaceuticals, Inc.(IONS)

Many Ionis Pharmaceuticals, Inc.(IONS) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Company shares were Reiterated by BMO Capital Markets on Dec 28, 2016 to Outperform, Raises Price Target to $ 68 from a previous price target of $61 .Company shares were Reiterated by Laidlaw on Dec 27, 2016 to Buy, Raises Price Target to $ 65 from a previous price target of $59 .Company shares were Reiterated by Leerink Partners on Dec 27, 2016 to Mkt Perform, Raises Price Target to $ 47 from a previous price target of $40 .

Company has reported several Insider transactions to the SEC, on Feb 8, 2017, Patrick R. Oneil (SVP, Legal & General Counsel) sold 1,500 shares at 46.33 per share price.On Jan 18, 2017, Sarah Boyce (Chief Business Officer) sold 1,361 shares at 46.29 per share price.On Jan 18, 2017, Brett P Monia (SVP, Antisense Drug Discovery) sold 2,502 shares at 46.29 per share price.

Ionis Pharmaceuticals Inc Last issued its quarterly earnings results on Nov 9, 2016. The company reported $0.06 EPS for the quarter, beating the analyst consensus estimate by $ 0.01. Analyst had a consensus of $0.05. The company had revenue of $110.90 million for the quarter, compared to analysts expectations of $113.10 million. The companys revenue was up 125.9% compared to the same quarter last year.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) has received a short term rating of buy from experts at Zacks with a rank of 2. The stock has been rated an average of 2.5 by 12 Brokerage Firm. 3 Wall Street Firms have rated the stock as a strong buys. 1 stock experts have also suggested a buy rating. 7 Brokerage Firms have advised hold. A sell rating was given by 1 analyst.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS): 10 analysts have set the short term price target of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) at $45.3. The standard deviation of short term price target has been estimated at $14.65, implying that the actual price may fluctuate by this value. The higher and the lower price estimates are $ 68 and $17 respectively.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) rose 1.95% or 0.9 points on Tuesday and made its way into the gainers of the day. After trading began at $47.26 the stock was seen hitting $47.26 as a peak level and $45.58 as the lowest level. The stock ended up at $46.99. The daily volume was measured at 1,004,309 shares. The 52-week high of the share price is $57 and the 52-week low is $19.5927. The company has a market cap of $5,695 million.

Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California.


Share this post

Leave a Reply